Novartis, a leading global pharmaceutical company, is purchasing Pikavation Therapeutics, a small biotech company owned by Synnovation Therapeutics, for up to $3 billion. This deal aims to bring new treatment options to patients with a specific type of breast cancer called HR+/HER2- breast cancer, as well as other advanced solid tumors (a group of cancers that spread beyond their original location).
The key focus of this acquisition is a new experimental drug called SNV4818, which is currently in early-stage testing (Phase I/II trials) for breast cancer and other advanced solid tumors. SNV4818 works by targeting a specific protein called PI3Kα, which is often overactive in cancer cells. Unlike older treatments, this new drug is designed to more precisely attack cancer cells while sparing healthy cells. This could lead to fewer side effects and better, longer-lasting results for patients.
Under the agreement, Novartis will pay Synnovation $2 billion upfront and up to $1 billion more if the drug meets certain future milestones, such as successful trial results or regulatory approvals. The company also believes that SNV4818 could be used alongside other cancer treatments like CDK inhibitors and hormone therapies to improve outcomes.
Synnovation’s CEO, Wenqing Yao, PhD, shared that the company will continue developing other promising drugs in its research pipeline, including a new cancer drug called SNV1521, which targets a different protein (PARP1), as well as other projects in oncology and immunology (diseases related to the immune system).
The acquisition is expected to be completed in the first half of 2026, pending standard regulatory approvals and other conditions. This deal is part of Novartis’s recent push to expand its research and development efforts in several areas, including neuroscience (brain and nervous system diseases), immunology, and cardiovascular (heart and blood vessel) conditions. In the past six months alone, Novartis has made major deals worth billions of dollars, including the $12 billion purchase of Avidity Biosciences, a $5.7 billion collaboration with Monte Rosa Therapeutics, and a $1.4 billion acquisition of Tourmaline Bio.
Other pharmaceutical companies, such as Gilead and Johnson & Johnson, are also investing heavily in developing new oral drugs for breast cancer and other solid tumors. For example, Gilead recently invested $3 billion in Kymera Therapeutics to develop a potential new treatment for prostate cancer, while Johnson & Johnson secured rights to a new class of cancer drugs through a $750 million licensing agreement with Halda Therapeutics.
This deal highlights the growing focus on developing more precise and effective cancer treatments with fewer side effects, offering hope to patients with limited options.